Zobrazeno 1 - 10
of 878
pro vyhledávání: '"Michael A. O'Donnell"'
Autor:
Mohamad Moussa, Mohamad Abou Chakra, Neal D. Shore, Athanasios Papatsoris, Yasser Farahat, Michael A. O’Donnell
Publikováno v:
Archivio Italiano di Urologia e Andrologia (2024)
Purpose: To understand the treatment plans suggested for BCG-unresponsive non-muscle invasive disease (NMIBC) patients in the Arab countries and therapeutic decisions applied for BCG-naive patients during BCG shortage time. Methods: A 10-minute onlin
Externí odkaz:
https://doaj.org/article/9c91914fb36a42a8ae93890e0f70d456
Autor:
Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Mohamad Abou Chakra, Yousef Zakharia, Michael A. O’Donnell
Publikováno v:
Cancers, Vol 16, Iss 14, p 2561 (2024)
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with salvage intravesical therapies. However, inherent or developed disease resistance, particularly a
Externí odkaz:
https://doaj.org/article/9da3287e9fa440b0a41b92f3c6f584ae
Autor:
Benjamin D. Plambeck, Tutku E. Tazegul, Ian M. McElree, Ryan L. Steinberg, Vignesh T. Packiam, Michael A. O'Donnell
Publikováno v:
Urology Case Reports, Vol 50, Iss , Pp 102516- (2023)
The presence of carcinoma in situ (CIS) is traditionally a contraindication to bladder-sparing approaches for muscle invasive bladder cancer (MIBC). Strategies that might aid in bladder preservation for this population require further investigation.
Externí odkaz:
https://doaj.org/article/9180241d453243fb861e86adb7a3f419
Autor:
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-16 (2017)
Abstract The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has dem
Externí odkaz:
https://doaj.org/article/a0d0c0551989418f9c28cf0b509924fb
Autor:
Joshua B. Kaelberer, Michael A. O'Donnell, Darrion L. Mitchell, Anthony N. Snow, Sarah L. Mott, John M. Buatti, Mark C. Smith, John M. Watkins
Publikováno v:
Prostate International, Vol 4, Iss 3, Pp 107-112 (2016)
Background: The current standard of care for men with muscle-invasive bladder cancer is radical cystoprostatectomy (RCP). One-third of RCP specimens demonstrate incidental prostate cancer, primarily reported in small series with limited follow-up. Th
Externí odkaz:
https://doaj.org/article/5a5f523e85dc408c8ddd8ca38a8232da
Autor:
Noah Frydenlund MS, Yousef Zakharia MD, Rohan Garje MD, Laila Dahmoush MBChB, Michael A. O’Donnell MD
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 6 (2018)
Urothelial carcinoma, the most common histologic subtype of bladder cancer in the United States, most frequently presents as non–muscle invasive disease. Initially, therapy involves transurethral endoscopic resection and subsequent intravesical the
Externí odkaz:
https://doaj.org/article/a9d238182764411aa330fb14a5ab85ff
Autor:
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-2 (2017)
Externí odkaz:
https://doaj.org/article/c82361f1610a4eca9e14db9abeff1c9b
Autor:
Henry M. Rosevear, Andrew J. Lightfoot, Michael A. O'Donnell, Charles E. Platz, Stefan A. Loening, Charles E. Hawtrey
Publikováno v:
The Scientific World Journal, Vol 11, Pp 1560-1567 (2011)
In the early 1950s, Rubin H. Flocks of the University of Iowa began to treat prostate cancer patients with colloidal gold (Au198) therapy, evolving his technique over nearly 25 years in 1515 patients. We reviewed the long-term outcomes of Flocks' pro
Externí odkaz:
https://doaj.org/article/d2ee6003c9294befaf40a8d19fce6297
Publikováno v:
The Scientific World Journal, Vol 11, Pp 602-613 (2011)
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are at high risk for recurrence and, more importantly, progression. Thus, both the American Urological Association and European Association of Urology
Externí odkaz:
https://doaj.org/article/9adc006e4aeb47eda4fe9d67637d3e81
Publikováno v:
Advances in Urology, Vol 2012 (2012)
Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunom
Externí odkaz:
https://doaj.org/article/bcc26fcad48542539f6d72edeec56776